

Index

Note: Page numbers of article titles are in **boldface** type.

- Abbott VISION analyzer, in blood cholesterol measurement, 76-82
- Accuracy, in blood cholesterol measurement, 39-52, 79-83
- Analyzers, in blood cholesterol measurement, 73-88
- performance of, 76-83
 - quality assurance in, 83-86
 - reliability of, 31-32, 47-49
 - systems suited to screening, 74-76
- Apolipoproteins, atherosclerosis risk and, 143-148
- characteristics of, 138-139
 - distribution of, 138-139
 - measurement of, 137-152
 - guidelines for, 148-150
 - immunosorbent assay in, 139-141
 - reference materials for, 112
 - reference methods in, 110
 - reference values for, 141-143
 - standardization in, 128. See also *NHBLI Lipid Standardization Program*.
- Atherosclerosis, apolipoproteins and, 143-148
- hypertriglyceridemia and, 169-172
- Bile acid sequestrants, in cholesterol control, 4, 25, 27
- Blood cholesterol, coronary heart disease risk and, 1-6
- desirable, follow-up care in, 20
 - in patient classification, low-density, 20-22
 - total, 18-20
 - low-density, in patient classification, 20-22
 - lowering of, in coronary heart disease risk, 1-6
 - diet in, 2-3
 - drugs in, 4
 - guidelines for, 17-27
 - dietary treatment in, 23-25
 - drug treatment in, 25-27
 - patient classification in, 18-22
- measurement of, 61-72
- analyzers in. See *Analyzers*.
 - chemical methods in, 67-68
 - enzymatic methods in, 68
 - equipment for, 84
 - problems with, 137-138
 - program design in, 84
 - protocols for, 85
 - quality assurance in, 83-86
 - recordkeeping in, 85
 - reference materials for, 85-86
 - reference methods in, 108-110
 - reliability of, 31-32, 37-60
 - accuracy in, 39-52, 79-83
 - analyzer considerations in, 47-49
 - intralaboratory precision/accuracy in, 44-52
 - Laboratory Standardization Panel report on, 43-44
 - matrix effect and, 49
 - precision in, 39-44, 51-52, 77-79
 - proficiency testing program in, 44-47
 - Quality Assurance Service database in, 44
 - reference materials and, 49-51
 - standardization in, 52-57. See also *NHBLI Lipid Standardization Program*.
 - sample collection in, 67
 - variability in, 70-71
 - regulation of, 3-4
 - screening for, 29-36. See also *Blood cholesterol, measurement of*.
 - in public sites, 30-31
 - justification for, 29-30
 - model systems for, 34
 - problems in, 31-34

- Blood cholesterol (*Continued*)
 screening for, strategies for, 30-31
 systems for, 74-76
 total, measurement of, 61-72
 versus apolipoproteins, in atherosclerosis
 risk prediction, 143-148
- Centers for Disease Control. See also
NHBLI Lipid Standardization Program.
 National Cholesterol Education Program
 support by, 128-131
- Cholesterol, high-density. See *High-density
 lipoprotein cholesterol*.
 in blood. See *Blood cholesterol*; *Hyper-
 cholesterolemia*.
 lipoproteins associated with, 64-66
 low-density. See *Low-density lipoprotein
 cholesterol*.
 receptors for, 3-4
 very low-density. See *Very low-density
 lipoprotein cholesterol*.
- Cholestyramine, in cholesterol control, 4, 25
- Chylomicrons, 62-63, 173
 detection of, in sample, 177
- Colestipol, in cholesterol control, 4, 25
- College of American Pathologists, profi-
 ciency testing program of, in accuracy
 evaluation, 44-47
 Quality Assurance Service database, in
 precision review, 44
- Coronary heart disease, cholesterol in, 1-6
 hypertriglyceridemia and, 153-168, 169-
 172
- Definitive methods, for cholesterol measure-
 ment, 90-93
- Diet therapy, in cholesterol lowering, 2-3,
 23-25
- Dysbetalipoproteinemia, 175
- Ektachem DT-60 analyzer, in blood chole-
 sterol measurement, 75-82
- Electrophoresis, in lipoprotein measure-
 ment, 181-182
- Enzyme-linked immunosorbent assay, in
 apolipoprotein measurement, 139-141
- Friedewald equation, cholesterol measure-
 ment, 64-65
- HDL. See *High-density lipoprotein chole-
 sterol*.
- High-density lipoprotein cholesterol, charac-
 teristics of, 61
 measurement of, 61-72
 reference methods in, 110
 triglycerides and, 163
 with compact analysis systems, 73-88
 synthesis of, 63
 triglyceride levels and, 170-171
 versus hypertriglyceridemia, 163-164
- HMG-CoA reductase inhibitors, in chole-
 sterol control, 4, 25, 27
- Hyperapobetalipoproteinemia, apolipopro-
 tein measurement in, 149
- Hypercholesterolemia, atherosclerosis and, 2
 coronary heart disease and, 1-5
 dietary influence on, 2-3
 genetic aspects of, 2
 molecular basis of, 3-4
 treatment of, compliance in, 32-33
 dietary, 23-25
 drugs in, 25-27
 physician readiness and, 33-34
- Hyperlipidemia, familial, 163
- Hypertriglyceridemia, 153-168. See also
Triglycerides.
 biochemistry of, 154
 clinical importance of, 169-172
 epidemiologic studies of, 154-164
 conclusions of, 160-163
 current literature on, 156-160
 problems with, 154-156
 pancreatitis in, 164, 172
 peripheral vascular disease and, 172
 screening for, 163-164
 severe, 172
- Immunosorbent assay, in apolipoprotein
 measurement, 139-141
- Immunonephelometric assay, in apolipopro-
 tein measurement, 139-140
- Immunturbidimetric assay, in apolipopro-
 tein measurement, 139-140
- LDL. See *Low-density lipoprotein chole-
 sterol*.
- Lipoproteins. See also *Apolipoproteins*;
Cholesterol.
 analysis of, fractions in, 20, 22
 apolipoproteins as measurement of, 137-
 138
 cholesterol associated with, 64-66
 classes of, 61-62
 measurement of, electrophoresis in, 181-
 182
 isolation of, 181-182
 reference materials for, 111-112

- separation in, 181-182
- standardization in. See *NHBLI Lipid Standardization Program*.
- ultracentrifugation in, 63-64, 66
- ultracycleride-rich. See also *Triglycerides*.
- physiology of, 173-174
- Lovastatin, in cholesterol control, 4, 25
- Low-density lipoprotein cholesterol, characteristics of, 61
 - high-risk levels of, 22
 - measurement of, 61-72
 - triglycerides and, 164
 - synthesis of, 63
 - triglyceride levels and, 171
- Low-density lipoproteins, metabolism of, 173-174
- Lp(a) lipoprotein, characteristics of, 62

- Model Systems for Blood Cholesterol
 - Screening program, 34

- National Cholesterol Education Program, 5, 7-15
 - activities of, 11-14
 - awareness surveys in, 8-10
 - impact of, 14-15
 - partnership approach of, 10-11
 - scientific base of, 7-8
 - support of, 128-131
- National Heart, Blood, Lung Institute Lipid Standardization Program. See *NHBLI Standardization Program*.
- National Institutes of Health conference on blood cholesterol lowering, 4-5
- National Reference System for Cholesterol, 89-104
 - background of, 89-92
 - clinical laboratory involvement with, 98-103
 - definitive methods of, 90-93
 - manufacturers involvement with, 96-97
 - organization involvement with, 97-98
 - reference laboratory network of, 95-96
 - reference materials of, 94-95
 - reference methods of, 91-94
- NHBLI Lipid Standardization Program, 105-135
 - design of, 112-120
 - history of, 105-108
 - methods used in, 120-122
 - participants in, 120-122
 - phases of, 116-117
 - resources for, 108-112
 - results of, 122-128
 - versus proficiency testing programs, 116-120

- Nicotinic acid, in cholesterol control, 25, 27

- Pancreatitis, in hypertriglyceridemia, 164, 172
- Peripheral vascular disease, hypertriglyceridemia and, 172
- Precision, in blood cholesterol measurement, 39-44, 51-52, 77-79
- Proficiency testing programs, in lipid measurement, 44-47, 116-120, 131

- Quality assurance, in cholesterol measurement, 83-86
 - in triglyceride measurement, 180-181

- Radioimmunoassay, in apolipoprotein measurement, 139-140
- Recordkeeping, in cholesterol measurement, 85
- Reference materials, for cholesterol measurement, 49-51, 85-86. See also *National Reference System for Cholesterol*.
- for lipid measurement, 111-112, 131
- Reference methods, for cholesterol measurement, 91-94
 - for lipid measurement, 108-110, 129-130
- Reflotron, in blood cholesterol measurement, 74-75, 78-82

- Screening, for blood cholesterol. See under *Blood cholesterol*.
- Standardization programs. See *NHBLI Lipid Standardization Program*.
- Step-One and Step-Two diets, in cholesterol lowering, 23-25

- Triglycerides. See also *Hypertriglyceridemia*.
 - biochemistry of, 154
 - food intake and, 174
 - high-density lipoprotein cholesterol and, 170-171
 - levels of, classification of, 154
 - measurement of, 68-69, 169-185
 - blanks in, 179-180
 - calibration in, 180
 - chemical methods in, 177-178
 - chylomicron detection and, 177
 - clinical importance of, 169-172
 - enzymatic methods in, 178-179

Triglycerides (*Continued*)

- measurement of, glycerol as contaminant in, 179-180
 - in overall lipid assessment, 174-176
 - lipoprotein separation in, 181-182
 - quality control in, 180-181
 - quantitation in, 177-179
 - reasons for, 163-164
 - reference methods in, 109
 - sample preparation in, 177
 - sampling conditions for, 176-177
 - specimen collection in, 176
 - standardization in. See also *NHBLI Lipid Standardization Program*.
 - with compact analysis systems, 73-88
 - very low-density lipoprotein cholesterol and, 171-172
- Ultracentrifugation, in cholesterol measurement, 63-64, 66
- Very low-density lipoprotein cholesterol,
 - beta form of, 65-66
 - characteristics of, 61
 - synthesis of, 63
 - triglyceride levels and, 171-172
 - Very low-density lipoproteins, synthesis of, 173-174
 - VISION analyzer, in blood cholesterol measurement, 76-82